Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

This study is testing whether adding low-dose radiation to specific sites, combined with immunotherapy and chemotherapy, can help prevent esophageal squamous cell cancer from returning in patients who have already completed radical (curative-intent) treatment. **You may be eligible if...** - You are between 18 and 80 years old - You have locally advanced esophageal squamous cell carcinoma that was treated with curative-intent chemoradiotherapy (this includes cases involving the cervical esophagus, T4 tumours, certain lymph node involvement, or cancers that couldn't be surgically removed) - Follow-up scans 2–3 weeks after completing radical treatment showed no sign of remaining tumour or spread - You are able to provide a tissue sample from your tumour - Your major organ function is normal and your performance status is 0 or 1 - Patients of childbearing potential must agree to use contraception **You may NOT be eligible if...** - You have a history of fistula (an abnormal opening) from the tumour invading nearby structures - You are at high risk of gastrointestinal bleeding or esophageal perforation - You have poor nutritional status - You experienced serious immune-related side effects (grade 3 or above) during prior treatment - You have interstitial lung disease, autoimmune diseases, or are on immunosuppressant medications - You have another active cancer Talk to your doctor to see if this trial is right for you.